Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 USD | +0.72% | +2.94% | +19.66% |
May. 13 | HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating | MT |
May. 09 | Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Financials (USD)
Sales 2024 * | 562K | Sales 2025 * | 7.36M | Capitalization | 105M |
---|---|---|---|---|---|
Net income 2024 * | -41M | Net income 2025 * | -42M | EV / Sales 2024 * | 148 x |
Net cash position 2024 * | 21.26M | Net Debt 2025 * | 12.33M | EV / Sales 2025 * | 15.9 x |
P/E ratio 2024 * |
-2.48
x | P/E ratio 2025 * |
-2.42
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.53% |
Latest transcript on Clearside Biomedical, Inc.
1 day | +0.72% | ||
1 week | +2.94% | ||
Current month | +11.11% | ||
1 month | +11.11% | ||
3 months | +0.72% | ||
6 months | +38.61% | ||
Current year | +19.66% |
Managers | Title | Age | Since |
---|---|---|---|
George Lasezkay
CEO | Chief Executive Officer | 72 | 17-08-07 |
Charles Deignan
DFI | Director of Finance/CFO | 59 | 11-12-31 |
Susan L. Coultas
CTO | Chief Tech/Sci/R&D Officer | - | 22-06-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
George Lasezkay
CEO | Chief Executive Officer | 72 | 17-08-07 |
Jeffrey Edwards
BRD | Director/Board Member | 63 | 18-09-25 |
Christy Shaffer
BRD | Director/Board Member | 66 | 11-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1.4 | +0.72% | 75,662 |
24-05-30 | 1.39 | +2.96% | 168,883 |
24-05-29 | 1.35 | -2.88% | 99,733 |
24-05-28 | 1.39 | +2.96% | 138,151 |
24-05-24 | 1.35 | -0.74% | 87,901 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.66% | 104M | |
+11.91% | 114B | |
+11.60% | 105B | |
-4.68% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-17.47% | 16.13B | |
+2.77% | 13.75B | |
+34.58% | 11.76B |
- Stock Market
- Equities
- CLSD Stock